The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC): A multicenter, single arm phase 2 trial (SAKK 06/19).
 
Richard Cathomas
Honoraria - Astellas Pharma (Inst); Janssen-Cilag; Merck KGaA (Inst)
Consulting or Advisory Role - Accord Healthcare (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sandoz (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst)
 
Martin Spahn
No Relationships to Disclose
 
Stefanie Hayoz
No Relationships to Disclose
 
Sabrina Chiquet
No Relationships to Disclose
 
Martina Schneider
No Relationships to Disclose
 
Cyrill A. Rentsch
No Relationships to Disclose
 
Sacha Rothschild
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Speakers' Bureau - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Roche Pharma AG (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Sanofi; Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health; Swiss Group for Clinical Cancer Research (SAKK) (Inst)
 
Ulf Petrausch
No Relationships to Disclose